Welcome to a new episode of Digital Health Interviews!Today, we dive into a brutally honest discussion about digital health with our guest, Sergei Polevikov. Sergei brings a wealth of experience and unfiltered insights into…
Continue Reading
What You Should Know:
– Tempus AI, a leader in artificial intelligence (AI)-powered precision medicine, filed with the Securities and Exchange Commission (SEC) on Monday to raise up to $100M in an initial public offering…
Continue Reading
What You Should Know:
– Tempus, a leader in artificial intelligence and precision medicine, announced a groundbreaking data contribution to the National Cancer Institute (NCI) today.
– The first-of-its-kind contribution will significantly enhance the NCI’s planned…
Continue Reading
As we kick off 2024, we wanted to start the new year with a series of 2024 Health IT predictions. We asked the Healthcare IT Today community to submit their predictions and we received…
Continue Reading
As we kick off 2024, we wanted to start the new year with a series of 2024 Health IT predictions. We asked the Healthcare IT Today community to submit their predictions and we received…
Continue Reading
Collaborating for biologic breakthroughs, IBM and Boehringer Ingelheim merge genAI with foundation models. IBM’s cutting-edge AI expedites antibody discovery, targeting diseases like cancer, autoimmune disorders, and infections. Boehringer’s validation of refined antibodies affirms in-silico…
Continue Reading
Welcome to the weekly edition of Healthcare IT Today Bonus Features. This article will be a weekly roundup of interesting stories, product announcements, new hires, partnerships, research studies, awards, sales, and more. Because there’s…
Continue Reading
Multinational pharmaceutical and biotech company Pfizer and AI-powered data company Tempus announced a multi-year strategic alliance to utilize AI and machine learning to inform drug discovery and development in oncology. Pfizer will leverage Tempus’ library…
Continue Reading
What You Should Know:– Today, the AI-powered genetic testing and precision medicine company Tempus announced that it has signed a significant strategic agreement with Pfizer to more precisely gather insights that will inform novel drug discovery…
Continue Reading
What You Should Know:– Tempus, the $10B artificial intelligence and precision medicine company, announced their first multi-omics collaboration with Actuate Therapeutics, in which datasets of different omic groups – genomics, transcriptomics, epigenomics, and others…
Continue Reading
